King's College London

Research portal

Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study

Research output: Contribution to journalArticle

Standard

Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis : A multi-national multi-database case-control study. / Newby, Danielle; Prieto-Alhambra, Daniel; Duarte-Salles, Talita; Ansell, David; Pedersen, Lars; Van Der Lei, Johan; Mosseveld, Mees; Rijnbeek, Peter; James, Glen; Alexander, Myriam; Egger, Peter; Podhorna, Jana; Stewart, Robert; Perera, Gayan; Avillach, Paul; Grosdidier, Solène; Lovestone, Simon; Nevado-Holgado, Alejo J.

In: Alzheimer's Research and Therapy, Vol. 12, No. 1, 38, 2020.

Research output: Contribution to journalArticle

Harvard

Newby, D, Prieto-Alhambra, D, Duarte-Salles, T, Ansell, D, Pedersen, L, Van Der Lei, J, Mosseveld, M, Rijnbeek, P, James, G, Alexander, M, Egger, P, Podhorna, J, Stewart, R, Perera, G, Avillach, P, Grosdidier, S, Lovestone, S & Nevado-Holgado, AJ 2020, 'Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study', Alzheimer's Research and Therapy, vol. 12, no. 1, 38. https://doi.org/10.1186/s13195-020-00606-5

APA

Newby, D., Prieto-Alhambra, D., Duarte-Salles, T., Ansell, D., Pedersen, L., Van Der Lei, J., ... Nevado-Holgado, A. J. (2020). Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. Alzheimer's Research and Therapy, 12(1), [38]. https://doi.org/10.1186/s13195-020-00606-5

Vancouver

Newby D, Prieto-Alhambra D, Duarte-Salles T, Ansell D, Pedersen L, Van Der Lei J et al. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. Alzheimer's Research and Therapy. 2020;12(1). 38. https://doi.org/10.1186/s13195-020-00606-5

Author

Newby, Danielle ; Prieto-Alhambra, Daniel ; Duarte-Salles, Talita ; Ansell, David ; Pedersen, Lars ; Van Der Lei, Johan ; Mosseveld, Mees ; Rijnbeek, Peter ; James, Glen ; Alexander, Myriam ; Egger, Peter ; Podhorna, Jana ; Stewart, Robert ; Perera, Gayan ; Avillach, Paul ; Grosdidier, Solène ; Lovestone, Simon ; Nevado-Holgado, Alejo J. / Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis : A multi-national multi-database case-control study. In: Alzheimer's Research and Therapy. 2020 ; Vol. 12, No. 1.

Bibtex Download

@article{775be9dff68f4bab88d51c3223a419ca,
title = "Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study",
abstract = "Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95{\%} CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95{\%} CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95{\%} CI 0.57-1.37). Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.",
keywords = "Anti-inflammatory drugs, Case-control study, Dementia, DMARDs, EMIF, European Medical Information Framework, Inflammation, Methotrexate, Rheumatoid arthritis, Sulfasalazine",
author = "Danielle Newby and Daniel Prieto-Alhambra and Talita Duarte-Salles and David Ansell and Lars Pedersen and {Van Der Lei}, Johan and Mees Mosseveld and Peter Rijnbeek and Glen James and Myriam Alexander and Peter Egger and Jana Podhorna and Robert Stewart and Gayan Perera and Paul Avillach and Sol{\`e}ne Grosdidier and Simon Lovestone and Nevado-Holgado, {Alejo J.}",
year = "2020",
doi = "10.1186/s13195-020-00606-5",
language = "English",
volume = "12",
journal = "Alzheimer's research & therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis

T2 - A multi-national multi-database case-control study

AU - Newby, Danielle

AU - Prieto-Alhambra, Daniel

AU - Duarte-Salles, Talita

AU - Ansell, David

AU - Pedersen, Lars

AU - Van Der Lei, Johan

AU - Mosseveld, Mees

AU - Rijnbeek, Peter

AU - James, Glen

AU - Alexander, Myriam

AU - Egger, Peter

AU - Podhorna, Jana

AU - Stewart, Robert

AU - Perera, Gayan

AU - Avillach, Paul

AU - Grosdidier, Solène

AU - Lovestone, Simon

AU - Nevado-Holgado, Alejo J.

PY - 2020

Y1 - 2020

N2 - Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.

AB - Background: Inflammatory processes have been shown to play a role in dementia. To understand this role, we selected two anti-inflammatory drugs (methotrexate and sulfasalazine) to study their association with dementia risk. Methods: A retrospective matched case-control study of patients over 50 with rheumatoid arthritis (486 dementia cases and 641 controls) who were identified from electronic health records in the UK, Spain, Denmark and the Netherlands. Conditional logistic regression models were fitted to estimate the risk of dementia. Results: Prior methotrexate use was associated with a lower risk of dementia (OR 0.71, 95% CI 0.52-0.98). Furthermore, methotrexate use with therapy longer than 4 years had the lowest risk of dementia (odds ratio 0.37, 95% CI 0.17-0.79). Sulfasalazine use was not associated with dementia (odds ratio 0.88, 95% CI 0.57-1.37). Conclusions: Further studies are still required to clarify the relationship between prior methotrexate use and duration as well as biological treatments with dementia risk.

KW - Anti-inflammatory drugs

KW - Case-control study

KW - Dementia

KW - DMARDs

KW - EMIF

KW - European Medical Information Framework

KW - Inflammation

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Sulfasalazine

UR - http://www.scopus.com/inward/record.url?scp=85083071675&partnerID=8YFLogxK

U2 - 10.1186/s13195-020-00606-5

DO - 10.1186/s13195-020-00606-5

M3 - Article

C2 - 32252806

AN - SCOPUS:85083071675

VL - 12

JO - Alzheimer's research & therapy

JF - Alzheimer's research & therapy

SN - 1758-9193

IS - 1

M1 - 38

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454